atai Life Sciences to Participate in September Investor Conferences
atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health treatments, has announced its participation in three major investor conferences this September.
The company will participate in fireside chat sessions at the Cantor Global Healthcare Conference on September 5th, the H.C. Wainwright Global Investment Conference on September 8th, and the TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17th. All presentations will be available via webcast on the company's investor relations website, with replays accessible after the events.
atai Life Sciences (NASDAQ: ATAI), azienda biofarmaceutica in fase clinica specializzata in trattamenti per la salute mentale, ha annunciato la sua partecipazione a tre importanti conferenze per investitori questo settembre.
L'azienda parteciperà a sessioni in formato fireside chat al Cantor Global Healthcare Conference il 5 settembre, all'H.C. Wainwright Global Investment Conference l'8 settembre e al TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit il 17 settembre. Tutte le presentazioni saranno trasmesse via webcast sul sito investor relations della società e le registrazioni saranno disponibili dopo gli eventi.
atai Life Sciences (NASDAQ: ATAI), una compañía biofarmacéutica en fase clínica centrada en tratamientos de salud mental, ha anunciado su participación en tres importantes conferencias para inversores este septiembre.
La compañía intervendrá en charlas tipo fireside chat en el Cantor Global Healthcare Conference el 5 de septiembre, en el H.C. Wainwright Global Investment Conference el 8 de septiembre y en el TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit el 17 de septiembre. Todas las presentaciones se emitirán por webcast en la web de relaciones con inversores de la compañía y las repeticiones estarán disponibles tras los eventos.
atai Life Sciences (NASDAQ: ATAI)는 정신건강 치료제에 주력하는 임상 단계의 바이오제약회사로, 이번 9월 세 곳의 주요 투자자 컨퍼런스에 참여한다고 발표했습니다.
회사는 9월 5일 Cantor Global Healthcare Conference, 9월 8일 H.C. Wainwright Global Investment Conference, 9월 17일 TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit에서 파이어사이드 챗 세션에 참석합니다. 모든 발표는 회사 IR 웹사이트를 통해 웹캐스트로 제공되며, 행사 후 다시보기도 이용 가능합니다.
atai Life Sciences (NASDAQ: ATAI), une société biopharmaceutique en phase clinique spécialisée dans les traitements de la santé mentale, a annoncé sa participation à trois grandes conférences investisseurs en septembre.
La société interviendra lors de sessions de type fireside chat au Cantor Global Healthcare Conference le 5 septembre, au H.C. Wainwright Global Investment Conference le 8 septembre et au TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit le 17 septembre. Toutes les présentations seront diffusées en webcast sur le site relations investisseurs de la société et les rediffusions seront accessibles après les événements.
atai Life Sciences (NASDAQ: ATAI), ein Bio‑Pharmaunternehmen in klinischer Phase mit Fokus auf Therapien für psychische Gesundheit, hat seine Teilnahme an drei großen Investorenkonferenzen im September angekündigt.
Das Unternehmen wird an Fireside‑Chat‑Sessions beim Cantor Global Healthcare Conference am 5. September, beim H.C. Wainwright Global Investment Conference am 8. September und beim TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit am 17. September teilnehmen. Alle Präsentationen werden per Webcast auf der Investor‑Relations‑Website des Unternehmens verfügbar sein; Aufzeichnungen stehen nach den Veranstaltungen zur Verfügung.
- None.
- None.
NEW YORK and AMSTERDAM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that its management is scheduled to participate in upcoming September investor conferences.
Details of the Company’s participation are as follows:
Cantor Global Healthcare Conference 2025
Format: Fireside Chat
Date: Friday, September 5th at 8:35 a.m. ET
Location: New York, NY
H.C. Wainwright 27th Annual Global Investment Conference
Format: Fireside Chat
Date and Time: Monday, September 8th at 11:30 a.m. ET
Location: New York, NY
TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Format: Fireside Chat
Date and Time: Wednesday, September 17th at 10:00 a.m. ET
Location: Virtual
The webcasts for the fireside chat will be available on atai’s website under Events on the Investors section of the atai website. Replays will be available following the live events.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. Our pipeline of psychedelic-based therapies includes BPL-003 (intranasal mebufotenin benzoate) for treatment-resistant depression (TRD), which is being advanced through a strategic investment with Beckley Psytech Limited; VLS-01 (buccal film DMT) also for TRD; and EMP-01 (oral R-MDMA) for social anxiety disorder. All three programs are in Phase 2 clinical development. We are also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. These programs aim to address the complex nature of mental health providing commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about our mission, visit www.atai.com or follow us on LinkedIn.
Contact Information
Investor Contact:
IR@atai.com
Media Contact:
PR@atai.com
FAQ
When is atai Life Sciences (ATAI) presenting at the Cantor Global Healthcare Conference 2025?
How can investors access atai Life Sciences' (ATAI) September 2025 conference presentations?
What type of company is atai Life Sciences (ATAI)?
Which investor conferences will atai Life Sciences (ATAI) attend in September 2025?
